（文章来源：每日经济新闻） 北大医药8月22日晚间发布公告称，程琴女士因个人原因申请辞去公司监事职务，且不再担任公司任何 职务。 ...

北大医药股份有限公司（以下简称"公司"）监事会于近日收到监事程琴女 士的书面辞职报告。程琴女士因个人原因申请辞去公司监事职务，且不再担任公 司任何职务。 程琴女士原定任期为 2024 年 6 月 27 日至 2027 年 6 月 26 日。根据《公司法》 及《公司章程》等相关规定，程琴女士的辞职不会导致公司监事会成员低于法定 最低人数，不会对公司日常经营管理产生重大影响，公司职工代表监事的比例亦 不低于三分之一，其辞职报告自送达公司监事会之日起生效。 截至本公告披露日，程琴女士未直接或间接持有公司股票，不存在应当履行 而未履行的承诺事项。 程琴女士任职期间在公司规范运作、防范风险、内控建设等方面发挥了积极 作用，公司对此表示衷心感谢！ 证券代码：000788 证券简称：北大医药 公告编号：2025-061 北大医药股份有限公司 关于公司监事离任的公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、监事离任情况 北大医药股份有限公司 监 事 会 二〇二五年八月二十三日 二、备查文件 1、《监事辞职报告》 特此公告。 ...

2025年8月22日，北大医药(000788.SZ)发布2025年中报。 公司营业总收入为9.57亿元。归母净利润为1.00亿元，较去年同报告期归母净利润增加1346.85万元，实现3年连续上涨，同比较去年同期上涨15.51%。经营 活动现金净流入为2310.77万元。 公司摊薄每股收益为0.17元，较去年同报告期摊薄每股收益增加0.02元，实现3年连续上涨，同比较去年同期上涨15.51%。 公司最新总资产周转率为0.42次。最新存货周转率为3.99次，较去年同期存货周转率增加0.46次，实现2年连续上涨，同比较去年同期上涨13.03%。 公司股东户数为5.53万户，前十大股东持股数量为2.17亿股，占总股本比例为36.42%，前十大股东持股情况如下： 公司最新资产负债率为31.21%，较上季度资产负债率减少1.57个百分点，较去年同期资产负债率减少6.87个百分点。 | 序号 | 股东名称 | 持股 | | --- | --- | --- | | l | 西南合成医药集团有限公司 | 22.2. | | 2 | 北大医疗管理有限责任公司 | 11.81 | | 3 | 北京政泉控股有限公司 | 0.54 | ...

公司摊薄每股收益为0.17元。 2025年8月22日，北大医药(000788.SZ)发布2025年中报。 公司营业总收入为9.57亿元，较去年同报告期营业总收入减少5081.88万元，同比较去年同期下降5.04%。归母净利润为1.00亿元。经营活动现金净流入为 2310.77万元，较去年同报告期经营活动现金净流入减少2846.17万元，同比较去年同期下降55.19%。 公司最新资产负债率为31.21%。 公司最新毛利率为25.83%，较去年同期毛利率减少3.07个百分点。最新ROE为6.28%。 公司较去年同期总资产周转率持平，同比较去年同期下降0.14%。最新存货周转率为3.99次。 公司股东户数为5.53万户，前十大股东持股数量为2.17亿股，占总股本比例为36.42%，前十大股东持股情况如下： | 序号 | 股东名称 | 持股 | | --- | --- | --- | | l | 西南合成医药集团有限公司 | 22.2. | | 2 | 北大医疗管理有限责任公司 | 11.81 | | 3 | 北京政泉控股有限公司 | 0.54 | | 4 | 袁绣峰 | 0.33 | | 5 | 刘尚红 | 0.2 ...

Group 1 - The company has revised its Articles of Association, merging similar clauses, deleting redundant ones, and adjusting wording for accuracy, while other provisions remain unchanged [1] - The company has also revised its attachments, renaming the "Rules of Procedure for Shareholders' Meetings" and making corresponding adjustments [1] - The revised Articles of Association and related documents are available on the company's official disclosure platform [1] Group 2 - The board of directors has proposed to the shareholders' meeting to authorize the management to handle the necessary business registration changes related to the revised Articles of Association [2] - The proposal is subject to approval by the shareholders' meeting [3] Group 3 - The company held its 13th meeting of the 11th board of directors on August 20, 2025, with all 8 directors present, complying with relevant regulations [5] - The meeting reviewed and approved the 2025 semi-annual report and profit distribution plan, with unanimous support from the directors [7][9] Group 4 - The profit distribution plan for the first half of 2025 proposes a cash dividend of 0.30 yuan per 10 shares, totaling approximately 17.88 million yuan, based on a total share capital of 595,987,425 shares [7][39] - The plan will be adjusted if the total share capital changes before implementation [7] Group 5 - The board approved a proposal to cooperate with a subsidiary in reducing its registered capital from 300 million yuan to 100 million yuan due to operational difficulties, followed by a liquidation process [11][46] - This decision aims to optimize the company's investment layout and mitigate operational risks [11][52] Group 6 - The company has decided to abolish the supervisory board, transferring its powers to the audit committee of the board, and will revise the relevant rules accordingly [14][28] - The proposal to amend the Articles of Association and related documents is also subject to shareholder approval [14][30]

Core Viewpoint - The company has announced its half-year report, detailing its financial performance, profit distribution plan, and future development strategies, emphasizing significant expected profit growth for 2024 [1][6]. Group 1: Financial Performance - The company plans to distribute a cash dividend of 0.30 yuan per 10 shares to all shareholders, based on a total of 595,987,425 shares [3]. - The projected net profit for 2024 is estimated to be between 115 million yuan and 145 million yuan, representing a year-on-year growth of 159.26% to 226.90% [6]. Group 2: Corporate Governance - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period [5]. - Several board members, including the chairman and other directors, have submitted resignation letters for personal reasons, indicating potential shifts in corporate governance [11][14][21]. Group 3: Related Party Transactions - The company anticipates daily related party transactions with Chongqing Southwest Synthetic Pharmaceutical Co., Ltd. not exceeding 13.04 million yuan and with Ping An Group and other related parties not exceeding 115.77 million yuan for 2025 [7]. - The company has identified that some related party transactions in 2024 exceeded the expected amounts and will be confirmed accordingly [7]. Group 4: Investment and Financing - The company plans to apply for a total bank credit line of 900 million yuan for operational needs, with guarantees provided for its wholly-owned subsidiaries [8]. - A new wholly-owned subsidiary is to be established with a registered capital of up to 30 million yuan to enhance the company's industry influence and international development [10]. Group 5: Regulatory Approvals - The company has received approval from the National Medical Products Administration for its product, injectable cefazolin sodium, confirming its consistency in quality and efficacy [17]. - Another product, ondansetron hydrochloride tablets, has also passed the same evaluation, indicating the company's commitment to maintaining high standards in its pharmaceutical offerings [19]. Group 6: Structural Changes - The company is revising its articles of association to eliminate the supervisory board, transferring its powers to the audit committee, which reflects a shift in governance structure [22][23].

Meeting Overview - The 13th meeting of the 11th Board of Directors of the company was held on August 20, 2025, in a hybrid format [1] - All 8 directors attended the meeting, with some participating via communication methods [1] - The meeting complied with relevant regulations, including the Company Law of the People's Republic of China [1] Financial Summary - The Board reviewed the company's actual operating performance for the first half of 2025 and prepared the half-year report and summary [1] - The profit distribution plan for the first half of 2025 was approved, proposing a cash dividend of 0.30 yuan per 10 shares, totaling 17,879,622.75 yuan [2] Capital Reduction and Liquidation - The company received a request from its associate, Beijing Peking University Medical Oncology Hospital Management Co., Ltd., to reduce its registered capital from 300 million yuan to 100 million yuan due to severe operational difficulties [2] - The company plans to cooperate with the associate's capital reduction and subsequent liquidation process to optimize its investment layout and mitigate operational risks [2] Governance Structure Adjustment - The company proposed to adjust its governance structure by abolishing the supervisory board, transferring its powers to the audit committee of the board [3] - The relevant rules and regulations regarding the supervisory board will be abolished, and amendments to the company's articles of association will be made accordingly [3] Next Steps - The profit distribution plan and governance structure adjustments are subject to approval at the company's shareholders' meeting [4]

Meeting Overview - The 8th meeting of the 11th Supervisory Board of the company was held on August 22, 2025, with all 5 supervisors present, including participation via communication methods [1][4] - The meeting was chaired by the Supervisory Board Chairman, and it complied with relevant regulations [1] Financial Summary - The company summarized its operational performance for the first half of 2025 and prepared the corresponding half-year report and summary [1] - The profit distribution plan for the first half of 2025 was approved, proposing a cash dividend of 0.30 yuan per 10 shares, totaling 17,879,622.75 yuan (including tax) [2] Capital Reduction and Liquidation - The company received a request from its associate, Beijing Peking University Medical Oncology Hospital Management Co., Ltd., to reduce its registered capital from 300 million yuan to 100 million yuan due to severe operational difficulties [2] - The company plans to cooperate with the associate's capital reduction and subsequent liquidation process to optimize its investment layout and mitigate operational risks [2] Governance Structure Adjustment - The company proposed to adjust its governance structure by abolishing the Supervisory Board, transferring its powers to the Audit Committee of the Board of Directors, and revising relevant rules and regulations [3] - This proposal requires approval from the shareholders' meeting [3]

Financial Overview - The total assets of the company at the end of the reporting period amounted to CNY 2,320,746,040.93, an increase from CNY 2,290,524,143.62 at the beginning of the period, reflecting a growth of approximately 1.32% [1][2][3] - Total liabilities decreased from CNY 776,415,444.06 to CNY 724,223,054.96, representing a decline of about 6.71% [2][3] - The total equity increased from CNY 1,514,108,699.56 to CNY 1,596,522,985.97, indicating a growth of approximately 5.46% [2][3] Revenue and Profitability - The total operating revenue for the first half of 2025 was CNY 957,309,406.16, down from CNY 1,008,128,208.10 in the same period of 2024, marking a decrease of about 5.04% [3][4] - Total operating costs decreased from CNY 897,060,160.66 to CNY 837,453,429.08, a reduction of approximately 6.65% [3][4] - The net profit for the first half of 2025 was CNY 100,293,909.16, compared to CNY 86,792,633.13 in the previous year, reflecting an increase of about 15.25% [4][5] Cash Flow - The net cash flow from operating activities was CNY 23,107,715.29, a decrease from CNY 51,569,414.20 in the previous year [6][7] - Cash and cash equivalents at the end of the period were CNY 562,916,068.85, down from CNY 586,430,669.66 at the beginning of the period [6][7] Expenses - Selling expenses decreased significantly from CNY 121,398,899.05 to CNY 66,029,184.50, a reduction of approximately 45.49% [4][5] - Research and development expenses increased from CNY 9,226,381.24 to CNY 11,833,550.53, reflecting a growth of about 28.38% [4][5] Earnings Per Share - Basic and diluted earnings per share for the first half of 2025 were CNY 0.1683, up from CNY 0.1457 in the same period of 2024, indicating an increase of approximately 15.93% [4][5]

证券代码：000788 证券简称：北大医药 公告编号：2025-059 北大医药股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北大医药股份有限公司（以下简称"公司"）于 2025 年 8 月 20 日召开第十 一届董事会第十三次会议、第十一届监事会第八次会议分别审议通过了《关于修 订 <公司章程> 及相关附件的议案》。根据中国证券监督管理委员会发布的《关于 新 <公司法> 配套制度规则实施相关过渡期安排》《上市公司章程指引》等相关法 律法规的规定，为进一步规范公司运作，结合公司实际情况, 公司拟调整治理结 构，不再设置监事会，监事会的职权由董事会审计委员会行使，公司《监事会议 事规则》等监事会相关制度相应废止。据此，公司拟对《公司章程》及其附件《股 东大会议事规则》《董事会议事规则》进行修订，具体如下： 一、《公司章程》修订情况 和《上市公司章程指引》等相关法律法规规定，公司不再设置监事会。《公司章 程》中对涉及"监事"、"监事会"的条款进行修订，删除"监事"、"监事会" 相关描述，涉及监事会或监事职权行使的表述修改为由审计委员会或审计委员会 ...